(Q73872763)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9366303%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

title

Dexamethasone, etoposide, ifosfamide, and cisplatin as second-line therapy in patients with aggressive non-Hodgkin's lymphoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9366303%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference

1 reference

1 reference

1 reference

N Haim

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9366303%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

M Ben-Shahar

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9366303%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

D Faraggi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9366303%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

A Tsuri-Etzioni

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9366303%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

M Leviov

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9366303%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

R Epelbaum

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9366303%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

language of work or name

English

0 references

publication date

1 November 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9366303%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9366303%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

volume

80

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9366303%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9366303%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

page(s)

1989-1996

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9366303%20AND%20SRC:MED&resulttype=core&format=json

Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide

7 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971115%2980%3A10%3C1989%3A%3AAID-CNCR17%3E3.0.CO%3B2-U

Salvage therapy for non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide, and cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971115%2980%3A10%3C1989%3A%3AAID-CNCR17%3E3.0.CO%3B2-U

National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971115%2980%3A10%3C1989%3A%3AAID-CNCR17%3E3.0.CO%3B2-U

Reporting results of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971115%2980%3A10%3C1989%3A%3AAID-CNCR17%3E3.0.CO%3B2-U

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971115%2980%3A10%3C1989%3A%3AAID-CNCR17%3E3.0.CO%3B2-U

The importance of dose intensity in chemotherapy of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971115%2980%3A10%3C1989%3A%3AAID-CNCR17%3E3.0.CO%3B2-U

Results of MIME salvage regimen for recurrent or refractory lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971115%2980%3A10%3C1989%3A%3AAID-CNCR17%3E3.0.CO%3B2-U

ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971115%2980%3A10%3C1989%3A%3AAID-CNCR17%3E3.0.CO%3B2-U

Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971115%2980%3A10%3C1989%3A%3AAID-CNCR17%3E3.0.CO%3B2-U

Salvage chemotherapy for lymphoma with VP-16, ifosfamide, and cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971115%2980%3A10%3C1989%3A%3AAID-CNCR17%3E3.0.CO%3B2-U

DICE (dexamethasone, ifosfamide, cisplatin, etoposide) as salvage therapy in non-Hodgkin's lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971115%2980%3A10%3C1989%3A%3AAID-CNCR17%3E3.0.CO%3B2-U

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971115%2980%3A10%3C1989%3A%3AAID-CNCR17%3E3.0.CO%3B2-U

EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971115%2980%3A10%3C1989%3A%3AAID-CNCR17%3E3.0.CO%3B2-U

Results of a salvage regimen in refractory or relapsed non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971115%2980%3A10%3C1989%3A%3AAID-CNCR17%3E3.0.CO%3B2-U

High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971115%2980%3A10%3C1989%3A%3AAID-CNCR17%3E3.0.CO%3B2-U

Mini-beam as salvage chemotherapy for refractory Hodgkin's disease and non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971115%2980%3A10%3C1989%3A%3AAID-CNCR17%3E3.0.CO%3B2-U

American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971115%2980%3A10%3C1989%3A%3AAID-CNCR17%3E3.0.CO%3B2-U

10.1002/(SICI)1097-0142(19971115)80:10<1989::AID-CNCR17>3.0.CO;2-U

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9366303%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference